David Eidelberg

List of Publications by Year
in descending order

222 papers	17,362 citations	11608 70 h-index	15218 126 g-index
226 all docs	226 docs citations	226 times ranked	11332 citing authors

#	Article	IF	Citations
1	Adaptive and pathological connectivity responses in Parkinsonâ€™s disease brain networks. Cerebral Cortex, 2023, 33, 917-932.	1.6	7
2	A replication study, systematic review and meta-analysis of automated image-based diagnosis in parkinsonism. Scientific Reports, 2022, 12, 2763.	1.6	8
3	The NADPARK study: A randomized phase I trial of nicotinamide riboside supplementation in Parkinsonâ€™s disease. Cell Metabolism, 2022, 34, 396-407.e6.	7.2	111
4	In utero exposure to maternal antiâ€“aquaporin-4 antibodies alters brain vasculature and neural dynamics in male mouse offspring. Science Translational Medicine, 2022, 14, eabe9726.	5.8	11
5	Abnormal metabolic covariance patterns associated with multiple system atrophy and progressive supranuclear palsy. Physica Medica, 2022, 98, 131-138.	0.4	9
6	Metabolic brain pattern in dementia with Lewy bodies: Relationship to Alzheimerâ€™s disease topography. NeuroImage: Clinical, 2022, 35, 103080.	1.4	13
7	Identification and validation of Alzheimerâ€™s disease-related metabolic brain pattern in biomarker confirmed Alzheimerâ€™s dementia patients. Scientific Reports, 2022, 12, .	1.6	13
8	Spectral guided sparse inverse covariance estimation of metabolic networks in Parkinson's disease. NeuroImage, 2021, 226, 117568.	2.1	18
9	Validation of the Alzheimer Disease Dementia Conversion-Related Pattern as an ATN Biomarker of Neurodegeneration. Neurology, 2021, 96, e1358-e1368.	1.5	11
10	Bloodâ€“brain barrier permeability in Parkinsonâ€™s disease patients with and without dyskinesia. Journal of Neurology, 2021, 268, 2246-2255.	1.8	6
11	Neuroimaging evaluation of deep brain stimulation in the treatment of representative neurodegenerative and neuropsychiatric disorders. Bioelectronic Medicine, 2021, 7, 4.	1.0	6
12	Dynamic ¹⁸F-FPCIT PET: Quantification of Parkinson Disease Metabolic Networks and Nigrostriatal Dopaminergic Dysfunction in a Single Imaging Session. Journal of Nuclear Medicine, 2021, 62, 1775-1782.	2.8	19
13	Neuropathological correlation supports automated image-based differential diagnosis in parkinsonism. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 3522-3529.	3.3	9
14	Stimulation of the Subthalamic Nucleus Changes Cortical-Subcortical Blood Flow Patterns During Speech: A Positron Emission Tomography Study. Frontiers in Neurology, 2021, 12, 684596.	1.1	4
15	Cognition-Related Functional Topographies in Parkinsonâ€™s Disease: Localized Loss of the Ventral Default Mode Network. Cerebral Cortex, 2021, 31, 5139-5150.	1.6	18
16	Analysis of the time course of COVID-19 cases and deaths from countries with extensive testing allows accurate early estimates of the age specific symptomatic CFR values. PLoS ONE, 2021, 16, e0253843.	1.1	6
17	Parkinson's disease-related pattern (PDRP) identified using resting-state functional MRI: Validation study. NeuroImage Reports, 2021, 1, 100026.	0.5	8
18	PET and SPECT Imaging in Atypical Parkinsonian Syndromes. , 2021, , 729-757.		0

#	Article	IF	Citations
19	Predictive Value of ¹⁸F-Florbetapir and ¹⁸F-FDG PET for Conversion from Mild Cognitive Impairment to Alzheimer Dementia. Journal of Nuclear Medicine, 2020, 61, 597-603.	2.8	30
20	Dyskinesia Matters. Movement Disorders, 2020, 35, 392-396.	2.2	42
21	Metabolic Network Abnormalities in Drugâ€NaÃ¯ve Parkinson's Disease. Movement Disorders, 2020, 35, 587-594.	2.2	19
22	LRRK2 and GBA Variants Exert Distinct Influences on Parkinsonâ€™s Disease-Specific Metabolic Networks. Cerebral Cortex, 2020, 30, 2867-2878.	1.6	35
23	Unique white matter structural connectivity in early-stage drug-naive Parkinson disease. Neurology, 2020, 94, e774-e784.	1.5	24
24	Radiomics and supervised machine learning in the diagnosis of parkinsonism with FDG PET: promises and challenges. Annals of Translational Medicine, 2020, 8, 808-808.	0.7	2
25	<scp>GBA</scp> Variants in Parkinson's Disease: Clinical, Metabolomic, and Multimodal Neuroimaging Phenotypes. Movement Disorders, 2020, 35, 2201-2210.	2.2	55
26	Reply to: Letter to Editor by Chaudhuri, Jenner, Antonini. Movement Disorders, 2020, 35, 901-901.	2.2	0
27	GDNF and Parkinsonâ€™s Disease: Where Next? A Summary from a Recent Workshop. Journal of Parkinson's Disease, 2020, 10, 875-891.	1.5	63
28	Atypical clinical presentation of pathologically proven Parkinson's disease: The role of Parkinson's disease related metabolic pattern. Parkinsonism and Related Disorders, 2020, 78, 1-3.	1.1	4
29	Differential diagnosis of parkinsonian syndromes: a comparison of clinical and automated - metabolic brain patternsâ€™ based approach. European Journal of Nuclear Medicine and Molecular Imaging, 2020, 47, 2901-2910.	3.3	23
30	Reproducible metabolic topographies associated with multiple system atrophy: Network and regional analyses in Chinese and American patient cohorts. NeuroImage: Clinical, 2020, 28, 102416.	1.4	12
31	Hemispheric Network Expression in Parkinsonâ€™s Disease: Relationship to Dopaminergic Asymmetries. Journal of Parkinson's Disease, 2020, 10, 1737-1749.	1.5	8
32	Use of positron-emission tomography as a diagnostic and differential diagnostic tool in parkinsonian syndromes. , 2020, , 313-329.		0
33	Serotonergic pathology and Braak's staging hypothesis in Parkinson's disease. Lancet Neurology, The, 2019, 18, 713-714.	4.9	8
34	Assessing cognitive impairment in SLE: examining relationships between resting glucose metabolism and anti-NMDAR antibodies with navigational performance. Lupus Science and Medicine, 2019, 6, e000327.	1.1	11
35	Network Imaging in Parkinsonian and Other Movement Disorders: Network Dysfunction and Clinical Correlates. International Review of Neurobiology, 2019, 144, 143-184.	0.9	6
36	Principal Components Analysis of Brain Metabolism Predicts Development of Alzheimer Dementia. Journal of Nuclear Medicine, 2019, 60, 837-843.	2.8	50

#	Article	IF	Citations
37	Network Structure and Function in Parkinsonâ€™s Disease. Cerebral Cortex, 2018, 28, 1-15.	1.6	39
38	Dopamine modulates striatal response to reward and punishment in patients with Parkinsonâ€™s disease. NeuroReport, 2018, 29, 532-540.	0.6	7
39	Switching Language Modes: Complementary Brain Patterns for Formulaic and Propositional Language. Brain Connectivity, 2018, 8, 189-196.	0.8	21
40	Reproducible network and regional topographies of abnormal glucose metabolism associated with progressive supranuclear palsy: Multivariate and univariate analyses in American and Chinese patient cohorts. Human Brain Mapping, 2018, 39, 2842-2858.	1.9	32
41	Disruption of network for visual perception of natural motion in primary dystonia. Human Brain Mapping, 2018, 39, 1163-1174.	1.9	4
42	ICâ€Pâ€045: SIMILAR METABOLIC BRAIN CHARACTERISTICS OF DEMENTIA WITH LEWY BODIES AND PARKINSON'S DISEASE DEMENTIA. Alzheimer's and Dementia, 2018, 14, P45.	0.4	0
43	ICâ€Pâ€073: ABNORMAL METABOLIC NETWORK ACTIVITY IN PARKINSON'S DISEASE WITH GBA VARIANTS. Alzheimer's and Dementia, 2018, 14, P65.	0.4	0
44	Gene therapy reduces Parkinsonâ€™s disease symptoms by reorganizing functional brain connectivity. Science Translational Medicine, 2018, 10, .	5.8	58
45	Visualizing Network Connectivity in Parkinson'S Disease. , 2018, , .		0
46	P3â€364: SIMILAR METABOLIC BRAIN CHARACTERISTICS OF DEMENTIA WITH LEWY BODIES AND PARKINSON'S DISEASE DEMENTIA. Alzheimer's and Dementia, 2018, 14, P1227.	0.4	0
47	A multivariate metabolic imaging marker for behavioral variant frontotemporal dementia. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2018, 10, 583-594.	1.2	20
48	The Age-Related Perfusion Pattern Measured With Arterial Spin Labeling MRI in Healthy Subjects. Frontiers in Aging Neuroscience, 2018, 10, 214.	1.7	49
49	The effects of image reconstruction algorithms on topographic characteristics, diagnostic performance and clinical correlation of metabolic brain networks in Parkinsonâ€™s disease. Physica Medica, 2018, 52, 104-112.	0.4	10
50	Network imaging biomarkers: insights and clinical applications in Parkinson's disease. Lancet Neurology, The, 2018, 17, 629-640.	4.9	120
51	Metabolic network expression in parkinsonism: Clinical and dopaminergic correlations. Journal of Cerebral Blood Flow and Metabolism, 2017, 37, 683-693.	2.4	51
52	Parkinson's disease-related network topographies characterized with resting state functional MRI. Human Brain Mapping, 2017, 38, 617-630.	1.9	62
53	Molecular imaging to track Parkinson's disease and atypical parkinsonisms: New imaging frontiers. Movement Disorders, 2017, 32, 181-192.	2.2	88
54	The effect of 18F-FDG-PET image reconstruction algorithms on the expression of characteristic metabolic brain network in Parkinsonâ€™s disease. Physica Medica, 2017, 41, 129-135.	0.4	23

#	Article	IF	Citations
55	Abnormal metabolic brain network associated with Parkinsonâ€™s disease: replication on a new European sample. Neuroradiology, 2017, 59, 507-515.	1.1	55
56	[ICâ€Pâ€035]: MONITORING THE PROGRESSION OF DEMENTIA USING FDGâ€PET BRAIN IMAGING AND NETWORK ANALYSIS: ROLE OF THE ALZHEIMER's DISEASEâ€RELATED PATTERN. Alzheimer's and Dementia, 2017, 13, P31.	0.4	0
57	Editorial: introducing the new Co-Editors-in-Chief of Current Opinion in Neurology. Current Opinion in Neurology, 2017, 30, 207.	1.8	1
58	Levodopa-induced abnormal involuntary movements correlate with altered permeability of the blood-brain-barrier in the basal ganglia. Scientific Reports, 2017, 7, 16005.	1.6	30
59	Current Opinions and Areas of Consensus on the Role of the Cerebellum in Dystonia. Cerebellum, 2017, 16, 577-594.	1.4	184
60	[P1â€“391]: MONITORING THE PROGRESSION OF DEMENTIA USING FGDâ€PET BRAIN IMAGING AND NETWORK ANALYSIS: ROLE OF THE ALZHEIMER's DISEASEâ€RELATED PATTERN. Alzheimer's and Dementia, 2017, 13, P416.	0.4	1
61	Imbalance of the direct and indirect pathways in focal dystonia: a balanced view. Brain, 2017, 140, 3075-3077.	3.7	10
62	Functional imaging in Huntington disease. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2017, 144, 263-287.	1.0	1
63	Long-term follow-up of a randomized AAV2-GAD gene therapy trial for Parkinsonâ€™s disease. JCI Insight, 2017, 2, e90133.	2.3	74
64	Increased putamen hypercapnic vasoreactivity in levodopa-induced dyskinesia. JCI Insight, 2017, 2, .	2.3	15
65	Longitudinal Changes in the Motor Learning-Related Brain Activation Response in Presymptomatic Huntington's Disease. PLoS ONE, 2016, 11, e0154742.	1.1	5
66	Modulation of Abnormal Metabolic Brain Networks by Experimental Therapies in a Nonhuman Primate Model of Parkinson Disease: An Application to Human Retinal Pigment Epithelial Cell Implantation. Journal of Nuclear Medicine, 2016, 57, 1591-1598.	2.8	18
67	Distinct brain networks underlie cognitive dysfunction in Parkinson and Alzheimer diseases. Neurology, 2016, 87, 1925-1933.	1.5	74
68	Knowledge gaps and research recommendations for essential tremor. Parkinsonism and Related Disorders, 2016, 33, 27-35.	1.1	46
69	Association ofGBAMutations and the E326K Polymorphism With Motor and Cognitive Progression in Parkinson Disease. JAMA Neurology, 2016, 73, 1217.	4.5	185
70	Dissociation of metabolic and hemodynamic levodopa responses in the 6-hydroxydopamine rat model. Neurobiology of Disease, 2016, 96, 31-37.	2.1	13
71	Automated Differential Diagnosis of Early Parkinsonism Using Metabolic Brain Networks: A Validation Study. Journal of Nuclear Medicine, 2016, 57, 60-66.	2.8	83
72	Flow-metabolism dissociation in the pathogenesis of levodopa-induced dyskinesia. JCI Insight, 2016, 1, e86615.	2.3	28

#	Article	IF	Citations
73	IC-P-078: Correlation between metabolic and CSF biomarkers in Alzheimer's disease patients with early cognitive decline. , 2015, 11, P56-P57.		1
74	Dopaminergic correlates of metabolic network activity in Parkinson's disease. Human Brain Mapping, 2015, 36, 3575-3585.	1.9	71
75	Reproducibility of a Parkinsonism-related metabolic brain network in non-human primates: A descriptive pilot study with FDG PET. Movement Disorders, 2015, 30, 1283-1288.	2.2	18
76	Abnormal Metabolic Pattern Associated with Cognitive Impairment in Parkinson'S Disease: A Validation Study. Journal of Cerebral Blood Flow and Metabolism, 2015, 35, 1478-1484.	2.4	46
77	Parkinson's Diseaseâ€"Related Spatial Covariance Pattern Identified with Resting-State Functional MRI. Journal of Cerebral Blood Flow and Metabolism, 2015, 35, 1764-1770.	2.4	43
78	P3-152: Correlation between metabolic and CSF biomarkers in Alzheimer's disease patients with early cognitive decline. , 2015, 11, P685-P686.		0
79	Metabolic resting-state brain networks in health and disease. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 2563-2568.	3.3	89
80	Thalamocortical Connectivity Correlates with Phenotypic Variability in Dystonia. Cerebral Cortex, 2015, 25, 3086-3094.	1.6	37
81	Effects of levodopa on regional cerebral metabolism and blood flow. Movement Disorders, 2015, 30, 54-63.	2.2	37
82	Functional Imaging to Study Movement Disorders. , 2015, , 201-212.		0
83	Human Radiation Dosimetry for the N-Methyl-d-Aspartate Receptor Radioligand ¹¹C-CNS5161. Journal of Nuclear Medicine, 2015, 56, 869-872.	2.8	10
84	Brain metabolism and autoantibody titres predict functional impairment in systemic lupus erythematosus. Lupus Science and Medicine, 2015, 2, e000074-e000074.	1.1	34
85	The visual perception of natural motion: abnormal task-related neural activity in DYT1 dystonia. Brain, 2015, 138, 3598-3609.	3.7	16
86	Parkinsonian differentiation using PCA image correlation scores. , 2015, , .		0
87	Assessing Cerebral Glucose Metabolism in Patients with Idiopathic Rapid Eye Movement Sleep Behavior Disorder. Journal of Cerebral Blood Flow and Metabolism, 2015, 35, 2062-2069.	2.4	61
88	18FDG-microPET and MR DTI findings in Tor1a+/â^' heterozygous knock-out mice. Neurobiology of Disease, 2015, 73, 399-406.	2.1	14
89	Quantifying Significance of Topographical Similarities of Disease-Related Brain Metabolic Patterns. PLoS ONE, 2014, 9, e88119.	1.1	26
90	Graph Theory-Guided Transcranial Magnetic Stimulation in Neurodegenerative Disorders. Bioelectronic Medicine, 2014, 1, 15-18.	1.0	5

#	Article	IF	Citations
91	Regional Brain Metabolism in a Murine Systemic Lupus Erythematosus Model. Journal of Cerebral Blood Flow and Metabolism, 2014, 34, 1315-1320.	2.4	23
92	Abnormal metabolic network activity in REM sleep behavior disorder. Neurology, 2014, 82, 620-627.	1.5	151
93	Radiation Absorbed Dose to the Basal Ganglia from Dopamine Transporter Radioligand¹⁸F-FPCIT. BioMed Research International, 2014, 2014, 1-5.	0.9	2
94	Characterization of diseaseâ€related covariance topographies with SSMPCA toolbox: Effects of spatial normalization and PET scanners. Human Brain Mapping, 2014, 35, 1801-1814.	1.9	41
95	A disease-specific metabolic brain network associated with corticobasal degeneration. Brain, 2014, 137, 3036-3046.	3.7	103
96	The Utility of Neuroimaging in the Differential Diagnosis of Parkinsonian Syndromes. Seminars in Neurology, 2014, 34, 202-209.	0.5	26
97	Consistent abnormalities in metabolic network activity in idiopathic rapid eye movement sleep behaviour disorder. Brain, 2014, 137, 3122-3128.	3.7	134
98	Brain network markers of abnormal cerebral glucose metabolism and blood flow in Parkinsonâ€™s disease. Neuroscience Bulletin, 2014, 30, 823-837.	1.5	34
99	The relationship between fasting serum glucose and cerebral glucose metabolism in late-life depression and normal aging. Psychiatry Research - Neuroimaging, 2014, 222, 84-90.	0.9	20
100	PET and SPECT Imaging in Parkinsonian Syndromes. , 2014, , 619-638.		1
101	Network modulation following sham surgery in Parkinsonâ€™s disease. Journal of Clinical Investigation, 2014, 124, 3656-3666.	3.9	65
102	Understanding the Anatomy of Dystonia: Determinants of Penetrance and Phenotype. Current Neurology and Neuroscience Reports, 2013, 13, 401.	2.0	16
103	Brain stimulation and functional imaging with fMRI and PET. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2013, 116, 77-95.	1.0	22
104	Parkinson's disease cognitive network correlates with caudate dopamine. NeuroImage, 2013, 78, 204-209.	2.1	83
105	Parkinson's Disease: Increased Motor Network Activity in the Absence of Movement. Journal of Neuroscience, 2013, 33, 4540-4549.	1.7	34
106	Metabolic Imaging of Bilateral Anterior Capsulotomy in Refractory Obsessive Compulsive Disorder: an FDG PET Study. Journal of Cerebral Blood Flow and Metabolism, 2013, 33, 880-887.	2.4	53
107	White matter changes in primary dystonia determined by 2D distribution analysis of diffusion tensor images. Journal of Magnetic Resonance Imaging, 2013, 37, 59-66.	1.9	7
108	Early registration of diffusion tensor images for group tractography of dystonia patients. Journal of Magnetic Resonance Imaging, 2013, 37, 67-75.	1.9	11

#	Article	IF	Citations
109	Different Î²-amyloid binding patterns in Alzheimer and Parkinson diseases. Neurology, 2013, 81, 516-517.	1.5	4
110	Metabolic changes in DYT11 myoclonus-dystonia. Neurology, 2013, 80, 385-391.	1.5	58
111	Metabolic network as a progression biomarker of premanifest Huntingtonâ€™s disease. Journal of Clinical Investigation, 2013, 123, 4076-4088.	3.9	91
112	Identification of Disease-related Spatial Covariance Patterns using Neuroimaging Data. Journal of Visualized Experiments, 2013, , .	0.2	43
113	Metabolic Networks in Parkinsonâ€™s Disease. , 2013, , 403-415.		3
114	Abnormal Metabolic Brain Networks in a Nonhuman Primate Model of Parkinsonism. Journal of Cerebral Blood Flow and Metabolism, 2012, 32, 633-642.	2.4	32
115	Functional brain networks in movement disorders. Current Opinion in Neurology, 2012, 25, 392-401.	1.8	31
116	Using imaging to identify psychogenic parkinsonism before deep brain stimulation surgery. Journal of Neurosurgery, 2012, 116, 114-118.	0.9	15
117	Improved Sequence Learning with Subthalamic Nucleus Deep Brain Stimulation: Evidence for Treatment-Specific Network Modulation. Journal of Neuroscience, 2012, 32, 2804-2813.	1.7	57
118	Functional Neuroimaging in Parkinson's Disease. Cold Spring Harbor Perspectives in Medicine, 2012, 2, a009274-a009274.	2.9	64
119	Functional brain imaging of cognitive dysfunction in Parkinson's disease. Journal of Neurology, Neurosurgery and Psychiatry, 2012, 83, 963-969.	0.9	43
120	Metabolic brain networks in translational neurology: Concepts and applications. Annals of Neurology, 2012, 72, 635-647.	2.8	130
121	Functional brain networks and abnormal connectivity in the movement disorders. NeuroImage, 2012, 62, 2261-2270.	2.1	100
122	Abnormal network topographies and changes in global activity: Absence of a causal relationship. NeuroImage, 2012, 63, 1827-1832.	2.1	14
123	Parkinson's disease tremor-related metabolic network: Characterization, progression, and treatment effects. NeuroImage, 2011, 54, 1244-1253.	2.1	216
124	Scaled subprofile modeling of resting state imaging data in Parkinson's disease: Methodological issues. NeuroImage, 2011, 54, 2899-2914.	2.1	152
125	Dopamine cell transplantation in Parkinson's disease: challenge and perspective. British Medical Bulletin, 2011, 100, 173-189.	2.7	15
126	Hereditary dystonia as a neurodevelopmental circuit disorder: Evidence from neuroimaging. Neurobiology of Disease, 2011, 42, 202-209.	2.1	159

#	Article	IF	Citations
127	Milestones in neuroimaging. Movement Disorders, 2011, 26, 868-978.	2.2	9
128	Impaired sequence learning in dystonia mutation carriers: a genotypic effect. Brain, 2011, 134, 1416-1427.	3.7	70
129	Brain networks in Huntington disease. Journal of Clinical Investigation, 2011, 121, 484-492.	3.9	69
130	Cerebellothalamocortical pathway abnormalities in torsinA DYT1 knock-in mice. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 6638-6643.	3.3	112
131	Differential diagnosis of parkinsonism: a metabolic imaging study using pattern analysis. Lancet Neurology, The, 2010, 9, 149-158.	4.9	291
132	Early Parkinson's disease: Longitudinal changes in brain activity during sequence learning. Neurobiology of Disease, 2010, 37, 455-460.	2.1	46
133	Imaging essential tremor. Movement Disorders, 2010, 25, 679-686.	2.2	80
134	Parkinson's Disease Spatial Covariance Pattern: Noninvasive Quantification with Perfusion MRI. Journal of Cerebral Blood Flow and Metabolism, 2010, 30, 505-509.	2.4	90
135	Dopamine Cell Implantation in Parkinson's Disease: Long-Term Clinical and ¹⁸F-FDOPA PET Outcomes. Journal of Nuclear Medicine, 2010, 51, 7-15.	2.8	164
136	Three-fold cross-validation of parkinsonian brain patterns. , 2010, 2010, 2906-9.		6
137	Abnormalities in Metabolic Network Activity Precede the Onset of Motor Symptoms in Parkinson's Disease. Journal of Neuroscience, 2010, 30, 1049-1056.	1.7	175
138	Increased sensorimotor network activity in DYT1 dystonia: a functional imaging study. Brain, 2010, 133, 690-700.	3.7	88
139	Abnormal metabolic brain networks in Parkinsonâ€™s disease. Progress in Brain Research, 2010, 184, 160-176.	0.9	26
140	18F-Fluorodeoxyglucose PET in the Evaluation of Parkinson Disease. PET Clinics, 2010, 5, 55-64.	1.5	36
141	Cerebellothalamocortical Connectivity Regulates Penetrance in Dystonia. Journal of Neuroscience, 2009, 29, 9740-9747.	1.7	279
142	Positron Emission Tomography Imaging. Frontiers of Neurology and Neuroscience, 2009, 25, 197-202.	3.0	0
143	Assessing the microlesion effect of subthalamic deep brain stimulation surgery with FDG PET. Journal of Neurosurgery, 2009, 110, 1278-1282.	0.9	59
144	Network biomarkers for the diagnosis and treatment of movement disorders. Neurobiology of Disease, 2009, 35, 141-147.	2.1	32

#	Article	IF	Citations
145	Metabolic networks for assessment of therapy and diagnosis in Parkinson's disease. Movement Disorders, 2009, 24, S725-31.	2.2	37
146	Metabolic brain networks in neurodegenerative disorders: a functional imaging approach. Trends in Neurosciences, 2009, 32, 548-557.	4.2	347
147	Learning and consolidation of visuo-motor adaptation in Parkinson's disease. Parkinsonism and Related Disorders, 2009, 15, 6-11.	1.1	107
148	Abnormal regional brain function in Parkinson's disease: truth or fiction?. NeuroImage, 2009, 45, 260-266.	2.1	48
149	Differential diagnosis of parkinsonian syndromes using PCA-based functional imaging features. NeuroImage, 2009, 45, 1241-1252.	2.1	102
150	Microstructural white matter changes in primary torsion dystonia. Movement Disorders, 2008, 23, 234-239.	2.2	103
151	Abnormal metabolic networks in atypical parkinsonism. Movement Disorders, 2008, 23, 727-733.	2.2	168
152	Dissociation of Metabolic and Neurovascular Responses to Levodopa in the Treatment of Parkinson's Disease. Journal of Neuroscience, 2008, 28, 4201-4209.	1.7	135
153	Dopaminergic Suppression of Brain Deactivation Responses during Sequence Learning. Journal of Neuroscience, 2008, 28, 10687-10695.	1.7	65
154	Metabolic correlates of subthalamic nucleus activity in Parkinson's disease. Brain, 2008, 131, 1373-1380.	3.7	75
155	New Strategies for Automated Differential Diagnosis of Degenerative Brain Disorders. Annual International Conference of the IEEE Engineering in Medicine and Biology Society, 2007, 2007, 3421-5.	0.5	4
156	Modulation of metabolic brain networks after subthalamic gene therapy for Parkinson's disease. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 19559-19564.	3.3	169
157	Increased cerebellar activation during sequence learning in DYT1 carriers: an equiperformance study. Brain, 2007, 131, 146-154.	3.7	99
158	PET Imaging in Parkinsons Disease. Current Medical Imaging, 2007, 3, 233-241.	0.4	1
159	L-Dopa infusion does not improve explicit sequence learning in Parkinson's disease. Parkinsonism and Related Disorders, 2007, 13, 146-151.	1.1	45
160	Imaging markers of mild cognitive impairment: Multivariate analysis of CBF SPECT. Neurobiology of Aging, 2007, 28, 1062-1069.	1.5	63
161	Correlates of movement initiation and velocity in Parkinson's disease: A longitudinal PET study. NeuroImage, 2007, 34, 361-370.	2.1	33
162	Metabolic brain networks associated with cognitive function in Parkinson's disease. NeuroImage, 2007, 34, 714-723.	2.1	309

#	Article	IF	Citations
163	Safety and tolerability of gene therapy with an adeno-associated virus (AAV) borne GAD gene for Parkinson's disease: an open label, phase I trial. Lancet, The, 2007, 369, 2097-2105.	6.3	949
164	Changes in network activity with the progression of Parkinson's disease. Brain, 2007, 130, 1834-1846.	3.7	360
165	Regional metabolic changes in Parkinsonian patients with normal dopaminergic imaging. Movement Disorders, 2007, 22, 167-173.	2.2	46
166	Gene transfer therapy for neurodegenerative disorders. Movement Disorders, 2007, 22, 1223-1228.	2.2	16
167	Abnormal Metabolic Network Activity in Parkinson'S Disease: Testâ€"Retest Reproducibility. Journal of Cerebral Blood Flow and Metabolism, 2007, 27, 597-605.	2.4	290
168	Subthalamic Glutamic Acid Decarboxylase Gene Therapy: Changes in Motor Function and Cortical Metabolism. Journal of Cerebral Blood Flow and Metabolism, 2007, 27, 501-509.	2.4	120
169	The assessment of neurological systems with functional imaging. Brain and Language, 2007, 102, 192-199.	0.8	10
170	Multivariate analysis: Applications to the study of hereditary movement disorders. Clinical Neuroscience Research, 2007, 6, 375-380.	0.8	1
171	Assessment of the progression of Parkinson's disease: a metabolic network approach. Lancet Neurology, The, 2007, 6, 926-932.	4.9	145
172	Quantification of Parkinsonâ€™s disease-related network expression with ECD SPECT. European Journal of Nuclear Medicine and Molecular Imaging, 2007, 34, 496-501.	3.3	72
173	Functional Imaging of Cerebral Blood Flow and Glucose Metabolism in Parkinsonâ€™s Disease and Huntingtonâ€™s Disease. Molecular Imaging and Biology, 2007, 9, 223-233.	1.3	52
174	PET Imaging in Parkinson's Disease and Other Neurodegenerative Disorders. , 2007, , 821-828.		7
175	Network modulation by the subthalamic nucleus in the treatment of Parkinson's disease. NeuroImage, 2006, 31, 301-307.	2.1	151
176	Anticholinesterase effect on motor kinematic measures and brain activation in Parkinson's disease. Movement Disorders, 2006, 21, 549-555.	2.2	7
177	Preclinical Huntington's disease: Compensatory brain responses during learning. Annals of Neurology, 2006, 59, 53-59.	2.8	106
178	Network modulation in the treatment of Parkinson's disease. Brain, 2006, 129, 2667-2678.	3.7	324
179	The metabolic pathology of dopa-responsive dystonia. Annals of Neurology, 2005, 57, 596-600.	2.8	60
180	A New Approach to Spatial Covariance Modeling of Functional Brain Imaging Data: Ordinal Trend Analysis. Neural Computation, 2005, 17, 1602-1645.	1.3	109

#	Article	IF	Citations
181	Neuroimaging and therapeutics in movement disorders. NeuroRx, 2005, 2, 361-371.	6.0	67
182	Positron Emission Tomography and Embryonic Dopamine Cell Transplantation in Parkinsonâ€™s Disease. , 2005, , 45-57.		3
183	Neuroimaging in human dystonia. Journal of Medical Investigation, 2005, 52, 272-279.	0.2	47
184	Neuroimaging and therapeutics in movement disorders. Neurotherapeutics, 2005, 2, 361-371.	2.1	0
185	Assessment of disease progression in parkinsonism. Journal of Neurology, 2004, 251, vii4-vii8.	1.8	5
186	Microstructural white matter changes in carriers of the DYT1 gene mutation. Annals of Neurology, 2004, 56, 283-286.	2.8	137
187	Executive processes in Parkinson's disease: FDG-PET and network analysis. Human Brain Mapping, 2004, 22, 236-245.	1.9	95
188	Caudate nucleus: influence of dopaminergic input on sequence learning and brain activation in Parkinsonism. NeuroImage, 2004, 21, 1497-1507.	2.1	107
189	Differential Cortical and Subcortical Activations in Learning Rotations and Gains for Reaching: A PET Study. Journal of Neurophysiology, 2004, 91, 924-933.	0.9	215
190	Learning networks in health and Parkinson's disease: Reproducibility and treatment effects. Human Brain Mapping, 2003, 19, 197-211.	1.9	72
191	Early stage Parkinson's disease patients and normal volunteers: Comparative mechanisms of sequence learning. Human Brain Mapping, 2003, 20, 246-258.	1.9	40
192	Impaired sequence learning in carriers of the DYT1 dystonia mutation. Annals of Neurology, 2003, 54, 102-109.	2.8	189
193	The differential effect of PD and normal aging on early explicit sequence learning. Neurology, 2003, 60, 1313-1319.	1.5	107
194	Evolving metabolic changes during the first postoperative year after subthalamotomy. Journal of Neurosurgery, 2003, 99, 872-878.	0.9	31
195	Title is missing!. Current Opinion in Neurology, 2003, 16, 471-474.	1.8	4
196	Relationships Among the Metabolic Patterns That Correlate With Mnemonic, Visuospatial, and Mood Symptoms in Parkinsonâ€™s Disease. American Journal of Psychiatry, 2002, 159, 746-754.	4.0	147
197	Modulation of regional brain function by deep brain stimulation: studies with positron emission tomography. Current Opinion in Neurology, 2002, 15, 451-455.	1.8	36
198	Pallidal stimulation for Parkinsonism: Improved brain activation during sequence learning. Annals of Neurology, 2002, 52, 144-152.	2.8	49

#	Article	IF	Citations
199	Dyskinesia after fetal cell transplantation for parkinsonism: A PET study. Annals of Neurology, 2002, 52, 628-634.	2.8	252
200	Primary dystonia: Is abnormal functional brain architecture linked to genotype?. Annals of Neurology, 2002, 52, 853-856.	2.8	119
201	Tc-99m ethylene cysteinate dimer SPECT in the differential diagnosis of parkinsonism. Movement Disorders, 2002, 17, 1265-1270.	2.2	86
202	Transplantation of Embryonic Dopamine Neurons for Severe Parkinson's Disease. New England Journal of Medicine, 2001, 344, 710-719.	13.9	2,253
203	Functional brain networks in Parkinson's disease. Parkinsonism and Related Disorders, 2001, 8, 91-94.	1.1	33
204	Blinded positron emission tomography study of dopamine cell implantation for Parkinson's disease. Annals of Neurology, 2001, 50, 181-187.	2.8	74
205	Metabolic changes following subthalamotomy for advanced Parkinson's disease. Annals of Neurology, 2001, 50, 514-520.	2.8	89
206	Functional correlates of pallidal stimulation for Parkinson's disease. Annals of Neurology, 2001, 49, 155-164.	2.8	107
207	Patterns of regional brain activation associated with different forms of motor learning. Brain Research, 2000, 871, 127-145.	1.1	344
208	PET Applications to Surgical Treatment of Parkinson's Disease. Loss,grief & Care, 2000, 8, 55-57.	0.2	0
209	Increased anterior cingulate and caudate activity in bipolar mania. Biological Psychiatry, 2000, 48, 1045-1052.	0.7	258
210	Positron emission tomographic studies in restless legs syndrome. Movement Disorders, 1999, 14, 141-145.	2.2	177
211	[11C]Raclopride-PET studies of the Huntington's disease rate of progression: Relevance of the trinucleotide repeat length. Annals of Neurology, 1998, 43, 253-255.	2.8	120
212	Functional brain networks in DYT1 dystonia. Annals of Neurology, 1998, 44, 303-312.	2.8	302
213	Asymmetric predominantly ipsilateral blepharospasm and contralateral parkinsonism in an elderly patient with a right mesencephalic cyst. Movement Disorders, 1998, 13, 135-139.	2.2	21
214	Differential diagnosis of parkinsonism with [18F]fluorodeoxyglucose and PET. Movement Disorders, 1998, 13, 268-274.	2.2	105
215	Quantitative Brain PET Comparison of 2D and 3D Acquisitions on the GE Advance Scanner. Molecular Imaging and Biology, 1998, 1, 135-144.	0.3	45
216	Functional brain networks in movement disorders. Current Opinion in Neurology, 1998, 11, 319-326.	1.8	57

#	Article	IF	Citations
217	Visualizing the evolution of abnormal metabolic networks in the brain using PET. Computerized Medical Imaging and Graphics, 1995, 19, 295-306.	3.5	23
218	Waht is it? Case 1, 1990: Progressive unilateral rigidity, bradykinesia, tremulousness, and apraxia, leading to fixed postural deformity of the involved limb. Movement Disorders, 1990, 5, 341-351.	2.2	24
219	Inferior Parietal Lobule. Archives of Neurology, 1984, 41, 843.	4.9	366
220	Symmetry and Asymmetry in the Human Posterior Thalamus. Archives of Neurology, 1982, 39, 325.	4.9	128
221	Brain Network Metabolic Changes in Patients with Parkinsonian Tremors. , 0, , .		0
222	Prospective F-18 FDOPA PET Imaging Study in Human PD. Nuclear Medicine and Molecular Imaging, 0, , 1.	0.6	3